Bio News
The U.S. Food and Drug Administration (FDA) approved rusfertide, a treatment for polycythemia vera developed by Takeda and Protagonist. Takeda will market the drug under the brand name Mimimiro for adults with abnormal increases in red blood cells. Mimimiro is priced at $4,200 per vial, and Jefferies projects peak annual sales of $2 billion.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
